Prognosia Breast, an AI-driven mammography tool, receives FDA Breakthrough Device status for improved five-year breast cancer risk prediction.
Key Details
- 1FDA granted Breakthrough Device designation to Prognosia Breast, an AI mammography analysis tool.
- 2Developed by Washington University School of Medicine experts.
- 3Tool predicts five-year breast cancer risk from mammogram findings.
- 4Claims to be twice as accurate as current risk assessment methods.
- 5Aims to inform decisions on supplemental imaging and genetic testing.
Why It Matters
FDA's recognition accelerates the path for advanced AI-enabled risk assessment in breast cancer screening. Improved prediction can enhance early intervention and personalisation, potentially reducing morbidity and mortality.
Source
Health Imaging
Related News
•Radiology Business
AI Workflow Enables General Radiologists to Match Breast Specialists in Screening
AI-powered workflow helps generalist radiologists detect breast cancer at rates comparable to specialists.
•Radiology Business
LLMs Automate Radiology Report Quality Control, Study Finds
LLM-based systems can rapidly automate radiology report quality control, saving significant manual review time.
•Radiology Business
Automation Bias: How AI Can Compromise Radiologist Accuracy
AI decision support can induce automation bias, leading radiologists to accept incorrect interpretations and potentially reduce their diagnostic accuracy.